Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of ADENUIRC is substantial. |
Clinical Added Value
| minor |
The Transparency Committee considers that ADENURIC provides a minor improvement in actual benefit (level IV) in the management of symptomatic chronic hyperuricaemia compared to the current therapeutic strategy based on allopurinol. |
eNq1mN9v2jAQx9/5K6K8kxC6QjoFqo21G1KrMVq0aS+VSY5iltrp2ebH/vo5hGp0ctRh8GNs53tn393HJyeX66fcWwIKylnPj4KW7wFLeUbZY8+f3F83Y/+y30gWZEn2lnWDVhC1fS/NiRA9v5wNpkCYCH7c3nwC/T+g3294CZ8uIJWv1ilJ8+ALEfNbUpRrvGTJaeY9gZzzrOcXSm5HvURI1F70Vxx/iYKkkIS7kf3ZxcO7/fEkLMX+Q1UJwBvCHo2iwKw0U4UITA6IhEeOmxp/z6y0qRiD4ApTGBE5HyFf0gwyo4kZyQVYGZmtsjvAZQ6yNGIUDxfpk7ASJwuyHsPz0Oz0Bz07kGvZbDWjbtzqnkVx3LnoxFamcO+ozFHQmwjTh7jd7UadEFhIMmAKaWoZmxFHSXJHUaFi8DqxHNlBeH4z+hkVRU42wUIUtkdFkOhpQF3+7jZS7uAeNZByfWb/6DOV5+GBXk92uHDkcUmjAVdM1lDjemx7EAPOJKzrI2oHOrne5SIFcTrZ35yZIT9S09yyNjXSNHQUCDkZD+uJdkoYfCQCJuiOBt8py/hKnJ4y+1F15H2xBaVRtMAsemhfxJ3o/Ny6iH7qFKq5Ya4U8gJCzR8qjsHKkM34sUDRWWmWesnJk6Xjts/hKcmhptNpWrJF5+FLY+Ys091VUTVhFP18dW+bHt8U4OZu+2mUplnvJbB23HUBc52LtX4fntlVgTtpgRWawTGXshDvw3C1WgVzIpqC6FMKZnhysO/dpe4acCcXdtXAVHB05Pq0uvUOi5Btob11pR/bpu7+37XDRhsSFRwRi4rJzsg5vDo9jP/2qM7cHr2ihzsz236SSMqZqz5HTY2KR+Ffh5Vdo+bD19mM1ryH1KZlElZvMf1GEpbvMP3GH/xY5SQ=
Mavmf4tARamys4dd
